| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g | |||
| Other Sizes |
Sodium Picosulfate is a laxative medication used for colon cleansing before colonoscopy, acts by inhibiting absorption of water and electrolytes, and increasing their secretion. As a laxative medicine, it can also be used in the treatment of constipation. It stimulates the movement within the intestines which helps facilitate the passage of stool. It is also used with other medicines for bowel cleansing before colonoscopy or surgery. This medicine is available in different dosage forms like oral solution, tablet, syrup.
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation Sodium picosulfate is not absorbed by the gastrointestinal tract, and its absorbed active metabolites are undetectable in breast milk. Lactating women can take sodium picosulfate without special precautions. ◉ Effects on Breastfed Infants No published information found as of the revision date. ◉ Effects on Lactation and Breast Milk No published information found as of the revision date. |
|---|---|
| References |
|
| Additional Infomation |
Sodium picosulfate is an aryl sulfate that belongs to the pyridine class of compounds.
|
| Molecular Formula |
C18H13NNA2O8S2
|
|---|---|
| Molecular Weight |
481.4
|
| Exact Mass |
480.9878
|
| CAS # |
10040-45-6
|
| PubChem CID |
68654
|
| Appearance |
Typically exists as solid at room temperature
|
| Melting Point |
272 - 275ºC
|
| LogP |
4.101
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
31
|
| Complexity |
633
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(=O)(=O)([O-])OC1C([H])=C([H])C(=C([H])C=1[H])C([H])(C1=C([H])C([H])=C([H])C([H])=N1)C1C([H])=C([H])C(=C([H])C=1[H])OS(=O)(=O)[O-].[Na+].[Na+]
|
| InChi Key |
GOZDTZWAMGHLDY-UHFFFAOYSA-L
|
| InChi Code |
InChI=1S/C18H15NO8S2.2Na/c20-28(21,22)26-15-8-4-13(5-9-15)18(17-3-1-2-12-19-17)14-6-10-16(11-7-14)27-29(23,24)25/h1-12,18H,(H,20,21,22)(H,23,24,25)/q2*+1/p-2
|
| Chemical Name |
4,4'-(2-Picolylidene)bis(phenylsulfuric acid) disodium salt
|
| Synonyms |
Sodium picosulphateSodium Picosulfate LA 391 Laxidogol Natrii picosulfas Picosulfate sodium Guttalax
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~207.72 mM)
H2O : ≥ 100 mg/mL (~207.72 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.19 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.19 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.19 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (207.72 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0773 mL | 10.3864 mL | 20.7727 mL | |
| 5 mM | 0.4155 mL | 2.0773 mL | 4.1545 mL | |
| 10 mM | 0.2077 mL | 1.0386 mL | 2.0773 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT04598880
Conditions:Colonic DiseasesLink: https://clinicaltrials.gov/ct2/show/NCT07218523
Conditions:Bowel Cleansing Prior to Clinical ProceduresLink: https://clinicaltrials.gov/ct2/show/NCT05436054
Conditions:Colon Disease
Title:TES RCT Fleet Enema vs Oral Mechanical Bowel Prep
Status:Recruiting
updateDate:2024-08-27
Ctid:NCT05148494
Link: https://clinicaltrials.gov/ct2/show/NCT05148494
Conditions:Colorectal Neoplasms|SurgeryLink: https://clinicaltrials.gov/ct2/show/NCT05726097
Conditions:Colon Cancer|Inflammatory Bowel Diseases|Gastrointestinal Bleed|Colon PolypLink: https://clinicaltrials.gov/ct2/show/NCT05144295
Conditions:Clinical Efficacy|Treatment Efficacy|Drug Side EffectLink: https://clinicaltrials.gov/ct2/show/NCT04593446
Conditions:Colorectal CancerLink: https://clinicaltrials.gov/ct2/show/NCT04153084
Conditions:Digestive IllnessLink: https://clinicaltrials.gov/ct2/show/NCT02765971
Conditions:Intestinal Recovery After Cesarean SectionLink: https://clinicaltrials.gov/ct2/show/NCT03074448
Conditions:Bowel PreparationLink: https://clinicaltrials.gov/ct2/show/NCT02239692
Conditions:Bowel CleansingLink: https://clinicaltrials.gov/ct2/show/NCT01554111
Conditions:Cathartic ColonLink: https://clinicaltrials.gov/ct2/show/NCT00885430
Conditions:Hemodynamics|HyponatremiaLink: https://clinicaltrials.gov/ct2/show/NCT00885274
Conditions:ColonoscopyLink: https://clinicaltrials.gov/ct2/show/NCT01689792
Conditions:Colorectal CancerLink: https://clinicaltrials.gov/ct2/show/NCT02211911
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT00576810
Conditions:ConstipationLink: https://clinicaltrials.gov/ct2/show/NCT01073930
Conditions:Bowel PreparationLink: https://clinicaltrials.gov/ct2/show/NCT01627171
Conditions:Endoscopy|Bowel Preparation SolutionsLink: https://clinicaltrials.gov/ct2/show/NCT01356407
Conditions:ColonoscopyLink: https://clinicaltrials.gov/ct2/show/NCT01073943
Conditions:Bowel PreparationLink: https://clinicaltrials.gov/ct2/show/NCT01292109
Conditions:Bowel CleanlinessLink: https://clinicaltrials.gov/ct2/show/NCT01093274
Conditions:Bowel PreparationLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003257-16
Condition:Colonoscopy bowel preparationKolonoszkópia előkészítésLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002811-33
Condition:Surgery proctologicalcirugía proctológicaLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001062-10
Condition:Bowel cleansingLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002186-30
Condition:Bowel cleansing prior to any procedure that requires a clean bowel, e.g. colonoscopy, surgical, video capsule or radiological procedures.Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001620-20
Condition:Cleansing of colonReinigung des DarmesLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005754-38
Condition:We do not use these products in a concrete disease. We compare the effectiveness of these products to obtain an accurate bowel cleansing before performing a capsule endoscopic study.No usamos estos productos en una patología en concreto, sino que nuestro objetivo es comparar la eficacia de ambos para obtener una adecuada limpieza intestinal en aquellos pacientes que van a ser sometidos a un estudio con cápsula endoscópicaLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004367-44
Condition:SENSORY AND MOTOR RESPONSE OF DESCENDING COLON TO DISTENSION WILL BE STUDIED IN HEALTHY SUBJECTSLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004327-21
Condition:bowel preparation before colonoscopydarmreiniging voor coloscopieLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004384-75
Condition:Patients who need a colonoscopy for screening, surveillance or diagnosis of a disease have to be prepared by bowel cleansingPatienten die een coloscopie moeten ondergaan vanwege screening, opvolging of diagnose van een ziekte moeten darmvoorbereiding krijgenLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002364-25
Condition:Patients with clinical symptoms or polyp history scheduled for either a diagnostic/surveillance colonoscopy or for a screening procedure in patients with a personal or familial risk of colon neoplasia.Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000587-10
Condition:� Subjects who are candidate to undergo colonoscopy:� Diagnosis� Screening� Follow-up after previous polipectomyLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016874-34
Condition:We are investigating the effect of mechanical bowel preparation, such as Picolax, on aerobic exercise capacity in healthy volunteers.Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003735-23
Condition:Bowel preparation prior to elective complete colonoscopy.As 'bowel preparation' is not a specific medical condition, there is no MedDRA term.Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001834-15
Condition:Pacientes de ambos sexos a los que se les vaya a realizar una exploración endoscópica colónica que precisara evacuación intestinal previaLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002087-10
Condition:To compare the efficacy and safety of 4 weeks treatment with sodium picosulphate Dulcolax®, Laxoberal® drops to placebo in patients with functional constipationLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001487-43
Condition:Gut cleansing prior to colonoscopy procedureProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
